{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:59:47Z","timestamp":1788011987389,"version":"build-2784847793"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health Pharmacoepidemiology","award":["5T32GM075766-17"],"award-info":[{"award-number":["5T32GM075766-17"]}]},{"name":"U.S. Department of Veterans Affairs CSR&D","award":["IK2 CX002203"],"award-info":[{"award-number":["IK2 CX002203"]}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR072583"],"award-info":[{"award-number":["P30AR072583"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["Rheumatology Research Training Grant T32-AR076951-"],"award-info":[{"award-number":["Rheumatology Research Training Grant T32-AR076951-"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Studies of dermatomyositis (DM) are frequently limited to single-centre cohorts. We used two large nationally representative US cohorts to conduct a descriptive epidemiological study of the characteristics, treatments and outcomes of patients with incident DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study identified two DM inception cohorts using (1) commercial claims and (2) electronic health record (EHR) data from the Excellence Network in Rheumatology to Innovate Care and High-impact research (ENRICH), a community rheumatology practice-based research network. Patient characteristics, treatments and healthcare utilisation were assessed using the 18 months before and 12 months after diagnosis in claims and the 12 months before and after diagnosis in EHR data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 2475 patients (claims) and 1196 patients (EHR) with incident DM. Among 998 patients in the EHR cohort with available laboratory data, 472 had available myositis panel results, with 165 (35.0%) having a positive myositis-specific antibody. Glucocorticoid use was common, 68.7% and 73.8% in the two cohorts, respectively, with initial doses most often &gt;20\u2009mg\/day; among glucocorticoid users, mean cumulative dose was 1407\u2009mg in the claims cohort. Hydroxychloroquine, methotrexate and mycophenolate were the most commonly used immunomodulatory therapies. During follow-up in the claims data cohort, incidence per 1000 person-years was 92.2, 15.3, 6.4, 2.9 and 2.1 for all-cause hospitalisation, malignancy, interstitial lung disease, gastrostomy tube placement and myocarditis, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Administrative claims and EHR data can be leveraged to assess treatment patterns and longitudinal outcomes\/disease manifestations in incident dermatomyositis cohorts. This study highlights a high burden of glucocorticoid exposure, significant heterogeneity in treatment and high healthcare utilisation in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006356","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:35:26Z","timestamp":1769528126000},"page":"e006356","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Characteristics, treatments and outcomes of patients with dermatomyositis using real-world data"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-2308","authenticated-orcid":false,"given":"Michael","family":"George","sequence":"first","affiliation":[{"name":"University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-4703","authenticated-orcid":false,"given":"Ellen","family":"Romich","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R","family":"Riley","sequence":"additional","affiliation":[{"name":"University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9649-3588","authenticated-orcid":false,"given":"Bryant R","family":"England","sequence":"additional","affiliation":[{"name":"VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA"},{"name":"University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanette","family":"Daigle","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1811-6602","authenticated-orcid":false,"given":"Emily E","family":"Holladay","sequence":"additional","affiliation":[{"name":"The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Su","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research, Birmingham, Alabama, USA"},{"name":"The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglong","family":"Xie","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research, Birmingham, Alabama, USA"},{"name":"The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim R","family":"Masri","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research, Birmingham, Alabama, USA"},{"name":"The University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"2026012707352132000_12.1.e006356.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220989"},{"key":"2026012707352132000_12.1.e006356.2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjd.14771","article-title":"Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis","volume":"176","author":"George","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026012707352132000_12.1.e006356.3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3111\/13696998.2016.1151433","article-title":"Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population","volume":"19","author":"Bradford Rice","year":"2016","journal-title":"J Med Econ"},{"key":"2026012707352132000_12.1.e006356.4","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1212\/WNL.0000000000001687","article-title":"Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial results","volume":"84","author":"Digre","year":"2015","journal-title":"Neurology (ECronicon)"},{"key":"2026012707352132000_12.1.e006356.5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2024.02.007","article-title":"Clinical characteristics and symptom progression of dermatomyositis subtypes: A retrospective analysis of a prospective database","volume":"91","author":"Pandya","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026012707352132000_12.1.e006356.6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaad.2017.12.074","article-title":"Dermatomyositis: A diagnostic dilemma","volume":"79","author":"Da Silva","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2026012707352132000_12.1.e006356.7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/RHU.0000000000001813","article-title":"Prevalent Drug Usage Practices in Adults and Children With Idiopathic Inflammatory Myopathies: Registry-Based Analysis From the MyoCite Cohort","volume":"28","author":"Mehta","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2026012707352132000_12.1.e006356.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2233"},{"key":"2026012707352132000_12.1.e006356.9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/acr.24786","article-title":"Incidence, Prevalence, and Mortality of Dermatomyositis: A Population-Based Cohort Study","volume":"75","author":"Kronzer","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012707352132000_12.1.e006356.10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00403-024-03104-y","article-title":"Sex-based differences in dermatomyositis: a retrospective study","volume":"316","author":"Lin","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2026012707352132000_12.1.e006356.11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-13-1"},{"key":"2026012707352132000_12.1.e006356.12","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/jamadermatol.2022.3112","article-title":"Incidence of Dermatomyositis in a Nationwide Cohort Study of US Veterans","volume":"158","author":"Bolender","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026012707352132000_12.1.e006356.13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.70067","article-title":"Generating Real-World Evidence From the Excellence Network in Rheumatology","volume":"33","author":"Beukelman","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026012707352132000_12.1.e006356.14","first-page":"1","article-title":"Validation of methods to identify people with idiopathic inflammatory myopathies using hospital episode statistics","volume":"6","author":"Hannah","year":"2022","journal-title":"Rheumatol Adv Pract"},{"key":"2026012707352132000_12.1.e006356.15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/acr.23010","article-title":"Validation of International Classification of Diseases Codes for the Epidemiologic Study of Dermatomyositis","volume":"69","author":"Kwa","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026012707352132000_12.1.e006356.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093161"},{"key":"2026012707352132000_12.1.e006356.17","unstructured":"Silberzweig A , Cohn E , Strunk E , et al . Validity of dermatomyositis case identification using diagnostic codes. Medical Dermatology Society 2024;1."},{"key":"2026012707352132000_12.1.e006356.18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000543803","article-title":"Validity of Diagnosis Codes to Identify a Dermatomyositis Cohort from Electronic Health Records","volume":"241","author":"Silberzweig","year":"2025","journal-title":"Dermatology"},{"key":"2026012707352132000_12.1.e006356.19","doi-asserted-by":"crossref","first-page":"152830","DOI":"10.1016\/j.semarthrit.2025.152830","article-title":"Identification of idiopathic inflammatory myopathy research cohorts using international classification of disease (ICD) codes: A systematic review","volume":"75","author":"Allenzara","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"2026012707352132000_12.1.e006356.20","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-022-02817-7"},{"key":"2026012707352132000_12.1.e006356.21","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S405660"},{"key":"2026012707352132000_12.1.e006356.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33011-7"},{"key":"2026012707352132000_12.1.e006356.23","doi-asserted-by":"crossref","unstructured":"Tang K , Zhang H , Jin H . Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department. Front Med (Lausanne) 2021;8. doi:10.3389\/fmed.2021.783416","DOI":"10.3389\/fmed.2021.783416"},{"key":"2026012707352132000_12.1.e006356.24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/atm-20-5175","article-title":"Dermatomyositis autoantibodies: how can we maximize utility?","volume":"9","author":"Hodgkinson","year":"2021","journal-title":"Ann Transl Med"},{"key":"2026012707352132000_12.1.e006356.25","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bjd.18133","article-title":"Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice","volume":"181","author":"Gandiga","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026012707352132000_12.1.e006356.26","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1007\/s10067-021-05797-2","article-title":"Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology","volume":"40","author":"G\u00f3mez","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2026012707352132000_12.1.e006356.27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027230","article-title":"Association between clinical phenotypes of dermatomyositis and polymyositis with myositis-specific antibodies and overlap systemic autoimmune diseases","volume":"100","author":"Chiang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026012707352132000_12.1.e006356.28","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1007\/s10067-025-07614-6","article-title":"A retrospective natural history study in adult and juvenile patients with incident dermatomyositis and polymyositis using real world data","volume":"44","author":"Barnes","year":"2025","journal-title":"Clin Rheumatol"},{"key":"2026012707352132000_12.1.e006356.29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11926-022-01060-y","article-title":"Glucocorticoids in Myositis: Initiation, Tapering, and Discontinuation","volume":"24","author":"Saygin","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"2026012707352132000_12.1.e006356.30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251877","article-title":"Acute healthcare resource utilization by age: A cohort study","volume":"16","author":"Tillmann","year":"2021","journal-title":"PLoS One"},{"key":"2026012707352132000_12.1.e006356.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16932"},{"key":"2026012707352132000_12.1.e006356.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81132-8"},{"key":"2026012707352132000_12.1.e006356.33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10067-021-05939-6","article-title":"Disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study","volume":"41","author":"Miyazaki","year":"2022","journal-title":"Clin Rheumatol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:35:31Z","timestamp":1769528131000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,27]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/rmdopen-2025-006356"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006356","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}